WU-NK-101 for Acute Myeloid Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML.
Who Is on the Research Team?
Cherry Thomas, MD
Principal Investigator
Wugen, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with Acute Myeloid Leukemia (AML) that has returned after treatment or hasn't responded to previous treatments. Participants should have had a stem cell transplant over 90 days ago, no severe organ disease, and an ECOG Performance Status of ≤2. They can't join if they have severe kidney issues, high blast counts without reduction therapy, uncontrolled infections or heart problems, recent investigational drug use, known allergies to study drugs, or are pregnant/nursing.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive WU-NK-101 in up to 3 Dose Levels until maximum tolerated dose or maximum administered dose is determined
Cohort Expansion
Further characterization of safety and tolerability, and determination of recommended phase 2 dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- WU-NK-101
WU-NK-101 is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wugen, Inc.
Lead Sponsor